Sanjeev Sethi1, Benjamin Madden2, Marta Casal Moura3, Samih H Nasr4, Nattawat Klomjit5, LouAnn Gross4, Vivian Negron4, M Cristine Charlesworth2, Mariam P Alexander4, Nelson Leung6, Ulrich Specks3, Fernando C Fervenza6, Mark Haas7. 1. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota sethi.sanjeev@mayo.edu. 2. Medical Genome Facility, Proteomics Core, Mayo Clinic, Rochester, Minnesota. 3. Division of Pulmonary and Critical Care, Department of Medicine, Mayo Clinic, Rochester, Minnesota. 4. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. 5. Division of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, Minnesota. 6. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. 7. Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
BACKGROUND: Membranous nephropathy (MN) is a common cause of proteinuria in patients receiving a hematopoietic stem cell transplant (HSCT). The target antigen in HSCT-associated MN is unknown. METHODS: We performed laser microdissection and tandem mass spectrometry (MS/MS) of glomeruli from 250 patients with PLA2R-negative MN to detect novel antigens in MN. This was followed by immunohistochemical (IHC)/immunofluorescence (IF) microscopy studies to localize the novel antigen. Western blot analyses using serum and IgG eluted from frozen biopsy specimen to detect binding of IgG to new 'antigen'. RESULTS: MS/MS detected a novel protein, protocadherin FAT1 (FAT1), in nine patients with PLA2R-negative MN. In all nine patients, MN developed after allogeneic HSCT (Mayo Clinic discovery cohort). Next, we performed MS/MS in five patients known to have allogeneic HSCT-associated MN (Cedar Sinai validation cohort). FAT1 was detected in all five patients by MS/MS. The total spectral counts for FAT1 ranged from 8 to 39 (mean±SD, 20.9±10.1). All 14 patients were negative for known antigens of MN, including PLA2R, THSD7A, NELL1, PCDH7, NCAM1, SEMA3B, and HTRA1. Kidney biopsy specimens showed IgG (2 to 3+) with mild C3 (0 to 1+) along the GBM; IgG4 was the dominant IgG subclass. IHC after protease digestion and confocal IF confirmed granular FAT1 deposits along the GBM. Lastly, Western blot analyses detected anti-FAT1 IgG and IgG4 in the eluate obtained from pooled frozen kidney biopsy tissue and in the serum of those with FAT1-asssociated MN, but not from those with PLA2R-associated MN. CONCLUSIONS: FAT1-associated MN appears to be a unique type of MN associated with HSCT. FAT1-associated MN represents a majority of MN associated with HSCT.
BACKGROUND: Membranous nephropathy (MN) is a common cause of proteinuria in patients receiving a hematopoietic stem cell transplant (HSCT). The target antigen in HSCT-associated MN is unknown. METHODS: We performed laser microdissection and tandem mass spectrometry (MS/MS) of glomeruli from 250 patients with PLA2R-negative MN to detect novel antigens in MN. This was followed by immunohistochemical (IHC)/immunofluorescence (IF) microscopy studies to localize the novel antigen. Western blot analyses using serum and IgG eluted from frozen biopsy specimen to detect binding of IgG to new 'antigen'. RESULTS: MS/MS detected a novel protein, protocadherin FAT1 (FAT1), in nine patients with PLA2R-negative MN. In all nine patients, MN developed after allogeneic HSCT (Mayo Clinic discovery cohort). Next, we performed MS/MS in five patients known to have allogeneic HSCT-associated MN (Cedar Sinai validation cohort). FAT1 was detected in all five patients by MS/MS. The total spectral counts for FAT1 ranged from 8 to 39 (mean±SD, 20.9±10.1). All 14 patients were negative for known antigens of MN, including PLA2R, THSD7A, NELL1, PCDH7, NCAM1, SEMA3B, and HTRA1. Kidney biopsy specimens showed IgG (2 to 3+) with mild C3 (0 to 1+) along the GBM; IgG4 was the dominant IgG subclass. IHC after protease digestion and confocal IF confirmed granular FAT1 deposits along the GBM. Lastly, Western blot analyses detected anti-FAT1 IgG and IgG4 in the eluate obtained from pooled frozen kidney biopsy tissue and in the serum of those with FAT1-asssociated MN, but not from those with PLA2R-associated MN. CONCLUSIONS: FAT1-associated MN appears to be a unique type of MN associated with HSCT. FAT1-associated MN represents a majority of MN associated with HSCT.
Authors: An S De Vriese; Richard J Glassock; Karl A Nath; Sanjeev Sethi; Fernando C Fervenza Journal: J Am Soc Nephrol Date: 2016-10-24 Impact factor: 10.121
Authors: Sanjeev Sethi; Benjamin J Madden; Hanna Debiec; M Cristine Charlesworth; LouAnn Gross; Aishwarya Ravindran; Amber M Hummel; Ulrich Specks; Fernando C Fervenza; Pierre Ronco Journal: J Am Soc Nephrol Date: 2019-05-06 Impact factor: 10.121
Authors: Sanjeev Sethi; Benjamin Madden; Hanna Debiec; Johann Morelle; M Cristine Charlesworth; LouAnn Gross; Vivian Negron; David Buob; Sidharth Chaudhry; Michel Jadoul; Fernando C Fervenza; Pierre Ronco Journal: J Am Soc Nephrol Date: 2021-04-08 Impact factor: 10.121
Authors: Francesca Fabretti; Nikolai Tschernoster; Florian Erger; Andrea Hedergott; Anja K Buescher; Claudia Dafinger; Bjoern Reusch; Vincent K Köntges; Stefan Kohl; Malte P Bartram; Lutz Thorsten Weber; Holger Thiele; Janine Altmueller; Bernhard Schermer; Bodo B Beck; Sandra Habbig Journal: Kidney Int Rep Date: 2021-01-29
Authors: Satoru Kudose; Miroslav Sekulic; Collette J Mehring; Dominick Santoriello; Ibrahim Batal; M Barry Stokes; Vivette D D'Agati; Glen S Markowitz Journal: Kidney Int Rep Date: 2021-05-04